VNTA
Ventana Biotech, Inc. is an emerging biotechnology enterprise focused on the lifecycle of drug candidates for personalized medicine, encompassing the identification, assessment, acquisition, development, and eventual commercialization through partnerships of relevant intellectual property. The company's primary therapeutic area is addressing obesity and its associated medical conditions. Notably, Ventana holds proprietary rights to a medicated chewing gum formulation that integrates an extract of hoodia gordonii and 2-hydroxyoleic acid. This unique composition is intended for the management of obesity, hypertension, and various other metabolic disorders. Ventana is actively engaged in developing these appetite-suppressant chewing gums into distinct products: a lower-dosage version aimed at the over-the-counter market, and a higher-dosage variant slated for distribution via pharmacists. The lower-strength product is expected to be retailed in drugstores and health food establishments. Established in 1989, Ventana Biotech, Inc. operates from Butschwil, Switzerland. The company adopted its current name in October 2008, having previously been known as Personalica, Inc.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | 0.00 | $801 | — |
| 2025 Q3 | 0.00 | $47,721 | — |
| 2025 Q2 | 0.00 | $65,255 | — |
| 2025 Q1 | 0.00 | $800 | — |
| 2025 Q4 | 0.00 | $800 | — |
| 2024 Q3 | -0.00 | $800 | — |
| 2024 Q2 | 0.00 | $19,000 | — |
| 2024 Q1 | 0.00 | $20,512 | — |